Allakos Inc

Allakos — Corporate Update (October 2020)

49 slides from Allakos's corporate update, Oct 26, 2020

  1. Slide 1: Corporate Update

    Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Diseases Corporate Update October 26, 2020 Exhibit 99.1

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (“Allakos,” the “Company,” “we” or “our”); the generation of future value; b

  3. Slide 3: Agenda

    Agenda Robert Alexander, PhD Overview 5:00 – 5:10 AM Henrik Rasmussen, MD PhD Subcutaneous formulation study results 5:10 – 5:15 AM Amol Kamboj, MD EG/EoD prevalence study results 5:15 – 5:35 AM Nicholas Talley, MD PhD & William Chey, MD Clinical implications of prevalence study results 5:35 – 5:45

  4. Slide 4: Overview

    Overview Robert Alexander, PhD CEO – Allakos

  5. Slide 5: Today's Update

    Today’s Update Phase 1 lirentelimab (AK002) subcutaneous data 63% bioavailability Well-tolerated (no injection site reactions or injection reactions) Sustained eosinophil suppression Results from prospective EGID prevalence study in patients with chronic functional GI symptoms 45% (181/405) of sympt

  6. Slide 6: Lirentelimab Executive Summary

    Lirentelimab Executive Summary Lirentelimab (AK002) has demonstrated activity in multiple inflammatory diseases Eosinophilic gastrointestinal diseases: EG, EoD, EoE (GI) Chronic urticaria (Skin) Indolent systemic mastocytosis (Systemic) Severe allergic conjunctivitis/atopic diseases (Eye) Phase 3 st

  7. Slide 7: Mast Cells and Eosinophils: Effector Cells Central to Inflammatory Responses

    Mast Cells and Eosinophils: Effector Cells Central to Initiating and Maintaining Inflammatory Responses Found at the Internal/External Interface of the Body In particular, in tissues and surrounding blood vessels and peripheral nerves Produce a Broad Range of Inflammatory Mediators Vasoactive amines

  8. Slide 8: Lirentelimab Targets Siglec-8 on Mast Cells and Eosinophils

    Lirentelimab Targets Siglec-8 on Mast Cells and Eosinophils Cell Membrane Activating Receptors Activation Siglec-8 Mast cell Eosinophil Inflammatory response lirentelimab Inhibition Mast cell Eosinophil Inhibition ADCC/Apoptosis AK002

  9. Slide 9: Mast Cells and Eosinophils Are Key Drivers of Inflammatory Disease

    Mast Cells and Eosinophils Are Key Drivers of Inflammatory Disease

  10. Slide 10: Eosinophils and Mast Cells Play a Significant Role in Many Diseases

    Eosinophils and Mast Cells Play a Significant Role in Many Diseases Mast Cell Activation Syndrome Indolent Systemic Mastocytosis Chronic Urticaria Atopic Dermatitis Eosinophilic Gastritis Eosinophilic Esophagitis Eosinophilic Duodenitis Ulcerative Colitis Vernal Keratoconjunctivitis GASTROINTESTINAL

  11. Slide 11: Eosinophilic Gastritis, Duodenitis, and Esophagitis

    Eosinophilic Gastritis (EG), Duodenitis (EoD), and Esophagitis (EoE) Chronic eosinophilic and mast cell inflammation of the stomach, duodenum, or esophagus Symptoms: abdominal pain, nausea, early satiety, loss of appetite, bloating, abdominal cramping, vomiting, diarrhea, and dysphagia No FDA-approv

  12. Slide 12: Phase 1 Subcutaneous Healthy Volunteer Study

    Phase 1 Subcutaneous Healthy Volunteer Study Henrik Rasmussen, MD PhD CMO - Allakos

  13. Slide 13: Phase 1 Subcutaneous Healthy Volunteer Study Design

    Phase 1 Subcutaneous Healthy Volunteer Study Study Design Phase 1 single-dose, randomized, double-blind, placebo-controlled study 58 adult healthy volunteers Dose groups: SC: lirentelimab 0.3, 1.0, 3.0, 5.0 mg/kg, 300 mg fixed (single 2 mL injection), or placebo IV: lirentelimab 1.0, 3.0 mg/kg

  14. Slide 14: Phase 1 Subcutaneous Healthy Volunteer Study Results

    Phase 1 Subcutaneous Healthy Volunteer Study Results 63% bioavailability Prolonged peripheral blood eosinophil suppression on lirentelimab Lirentelimab was well tolerated No injection site reactions or injection reactions No treatment related adverse events No serious adverse events Placebo 1 mild (

  15. Slide 15: SC Lirentelimab Showed Sustained Depletion of Eosinophils in Healthy Volunteers

    SC Lirentelimab Showed Sustained Depletion of Eosinophils in Healthy Volunteers in Phase 1 Study Route Dose Cohort (mg/kg) n Baseline 1 hr 3 hr Day 15 Day 35 Day 56 Day 85 SC Placebo 10 100 100 200 200 100 200 100 0.3 6 110 200 20 0 0 50 100 1.0 6 150 0 0 0 0 0 50 3.0 6 150 0 0 0 0 0 0 5.0 6 100 0 0

  16. Slide 16: EG/EoD Prevalence Study

    EG/EoD Prevalence Study Amol Kamboj, MD Senior Medical Director - Allakos

  17. Slide 17: ENIGMA: Unexpectedly High Diagnosis Rate of EG/EoD Among Undiagnosed Patients

    ENIGMA: Unexpectedly High Diagnosis Rate of EG/EoD Among Previously Undiagnosed Patients 51 patients without history of EG/EoD entered ENIGMA screening 51% (26/51) met symptom criteria for endoscopy and biopsy 58% (15/26) EG / EoD Suggests significant underdiagnosis of EG/EoD in GI patient populatio

  18. Slide 18: De Novo EG/EoD Patients Had Similar Response to Lirentelimab

    De Novo EG/EoD Patients Had a Similar Response to Lirentelimab as Patients with a Prior History of EG/EoD Improvement in TSS-8 From Baseline Weeks 69-70 3.0 mg/kg lirentelimab TSS-8 Mean % Δ from ENIGMA BL Placebo Weeks 13-14 De Novo (n=6) Prior Dx (n=14) De Novo (n=6) Prior Dx (n=23) De Novo (n=5)

  19. Slide 19: Similar Response to Lirentelimab Regardless of History of EG/EoD

    Similar Response to Lirentelimab Regardless of History of EG/EoD Proportion of Patients with ≥50% Improvement in TSS-8 % of Patients Weeks 69-70 Placebo Weeks 13-14 De novo: Newly diagnosed EG/EoD Prior Dx: Patients with diagnosis of EG/EoD prior to screening for ENIGMA OLE data as of 28SEP20 (1/5)

  20. Slide 20: EG/EoD Prevalence Study Study Design

    EG/EoD Prevalence Study Study Design Prospective, multi-center study to assess the prevalence of EG/EoD in symptomatic patients with chronic functional GI symptoms At least a 6-month history of abdominal pain, abdominal cramping, nausea, vomiting, diarrhea, bloating or early satiety without identifi

  21. Slide 21: Symptoms Assessed With the Same PRO Questionnaire Used in ENIGMA

    Symptoms Assessed With the Same PRO Questionnaire Used in ENIGMA and Phase 3 ENIGMA 2 Abdominal pain Nausea Early satiety Vomiting Loss of appetite Abdominal cramping Bloating Diarrhea Developed in accordance with FDA guidance on PRO development Captures the GI symptoms of patients on a daily basis

  22. Slide 22: Systematic Biopsy Protocol

    Systematic Biopsy Protocol Stomach Duodenum Biopsy Protocol 4 biopsies from the duodenum, 2 each from the descending and horizontal parts GASTRIC ANTRUM: 4 biopsies (2-5 cm proximal to the pylorus) GASTRIC CORPUS: 4 biopsies (2 from the proximal lesser curvature and 2 from the greater curvature)

  23. Slide 23: High Prevalence of Chronic GI Patients Who Met Histologic Criteria for EG/EoD

    High Prevalence of Chronic GI Patients Who Met Histologic Criteria for EG/EoD 73% Met Symptom Criteria & Biopsied n=405 45% Met Histologic Criteria for EG/EoD1 n=181 5% Did Not Meet Histologic Criteria for EG/EoD or MGID n=20 50% Met Histologic Criteria for MGID2 n=204 Entered Screening n=556 33% (1

  24. Slide 24: Patients Were Screened from Multiple Sites Across the U.S.

    Patients Were Screened from Multiple Sites Across the U.S. Consistent discovery rate of EG/EoD across regions

  25. Slide 25: Baseline Characteristics of Patients in Prevalence Study Compared to ENIGMA

    Baseline Characteristics of Patients in Prevalence Study Compared to ENIGMA Patient Characteristics Screened n=556 EG/EoD n=181 MGID n=204 ENIGMAa n=72 Mean age, years (range) 45 (18–83) 45 (19–78) 44 (18–76) 42 (18-74) Female sex 72% 73% 72% 60% White 89% 85% 90% 92% Weight, median, kg 82 83 82 82

  26. Slide 26: Comparable Symptom Profile in Prevalence Study vs. ENIGMA

    Comparable Symptom Profile in Prevalence Study vs. ENIGMA Symptom Mean Symptom Intensity During Screening (0-10) Early Satiety Bloating Abdominal Pain Abdominal Cramping Loss of Appetite Nausea Diarrhea Vomiting Prevalence Study EG/EoD (n=181), TSS=31 ENIGMA De Novo EG/EoD (n=15), TSS=32 ENIGMA with

  27. Slide 27: Eosinophil and Mast Cells Display an Activated Phenotype

    Eosinophil and Mast Cells from Symptomatic Patients in the Prevalence Study Display an Activated Phenotype * p<0.05; ** p<0.01; *** p<0.001; **** p <0.0001 compared to mean expression of HV control MCs or eosinophils 1Patients who met symptom criteria and ≥30 eos/hpf in 5 gastric hpfs and/or ≥30 eos

  28. Slide 28: Prevalence Study Summary

    Prevalence Study Summary Many symptomatic patients had activated eosinophils and mast cells, likely contributing to disease despite not meeting histologic criteria for EG/EoD Patients are not well managed by available therapies and there are no approved therapies targeting eosinophils and mast cells

  29. Slide 29: Implications of Prevalence Study Results

    Implications of Prevalence Study Results Nicholas J. Talley, MD William D. Chey, MD

  30. Slide 30: Expert Panel

    Expert Panel Laureate Professor, Univ. of Newcastle Gastroenterologist & Epidemiologist Past Chairman of Medicine, Mayo Clinic APFED Medical Advisory Panel Member Past Co-editor-in-Chief of the American Journal of Gastroenterology Nicholas J. Talley, MD PhD Professor, Gastroenterology, Univ. of Mich

  31. Slide 31: Strengths of Prevalence Study

    Strengths of Prevalence Study First large prospective study looking at prevalence of EG/EoD Consistent findings across U.S. geographical locations Study population highly representative of a typical community GI practice 500+ patients screened and evaluated across 20 sites, with 400+ undergoing endo

  32. Slide 32: Projected 6-10 Million Adult Patients With Treatment Refractory Functional GI Disorders

    Projected 6-10 Million Adult Patients With Treatment Refractory Functional GI Disorders in the United States Total Adult GI Patients in a GI Practice Diagnosed and Treated for FGID, GERD, or Chronic Gastritis Inadequately Controlled ~6-10MM Base Assumption, n (%) Source 14,000 GIs1 x 1,600/2,000 pts

  33. Slide 33: Study Findings Substantiate Pathogenic Role of Eosinophils and Mast Cells

    Study Findings Substantiate the Pathogenic Role of Eosinophils and Mast Cells in Patients with Chronic GI Symptoms Non-ulcer Dyspepsia and Duodenal Eosinophilia: An Adult Endoscopic Population-Based Case-Control Study Eos were significantly elevated in FD patients Study 1: Functional Dyspepsia & Eos

  34. Slide 34: Guidelines Do Not Call for EGDs Unless Alarm Signs Are Present

    Guidelines do not call for EGDs unless alarm signs are present Current State Implications EGD should be performed for patients with moderate-to-severe symptoms, refractory to SoC EGD 1 Biopsy 2 Biopsies are generally limited to areas of interest or where mucosa appears macroscopically abnormal Histo

  35. Slide 35: Summary

    Summary Historically, EGDs & biopsies have not been recommended in patients with chronic GI symptoms because it did not guide patient management Current treatments remain ineffective for many patients with chronic functional GI symptoms, likely because these interventions do not address underlying p

  36. Slide 36: ENIGMA Open-Label Extension Study Update

    ENIGMA Open-Label Extension Study Update Henrik Rasmussen, MD PhD CMO – Allakos

  37. Slide 37: OLE Interim Analysis Patient Population

    OLE Interim Analysis Patient Population 58 of 59 eligible patients entered the OLE study As of 9/28/2020, 45 patients have completed ≥52 weeks of lirentelimab treatment (includes ENIGMA exposure) Average ~78 weeks of lirentelimab treatment 13 patients have discontinued with <52 weeks of lirentelimab

  38. Slide 38: Substantial Symptom Improvement Over Time

    Substantial Symptom Improvement Over Time Time on lirentelimab (Weeks)a EG/EoD-PRO Total Symptom Score-8 Dose TSS-8 Mean ± SEM % Δ from ENIGMA BL BL aTotal lirentelimab exposure, inclusive of lirentelimab exposure during the Phase 2 ENIGMA study Data as of 28SEP2020

  39. Slide 39: Change in Symptoms Over Time in Patients with ≥70 Weeks of Treatment

    Change in Symptoms Over Time in Patients with ≥70 Weeks of Lirentelimab Treatment aTotal lirentelimab exposure, inclusive of lirentelimab exposure during the Phase 2 ENIGMA study Data as of 28SEP2020 Total Lirentelimab Exposure (Weeks)a TSS Mean Change from ENIGMA BL (n=29) Baseline Absolute Percent

  40. Slide 40: Change in Symptom Response Rate in Patients with ≥70 Weeks of Treatment

    Change in Symptom Response Rate in Patients with ≥70 Weeks of Lirentelimab Treatment 29-30 ≥50% Response ≥70% Response ≥90% Response Weeksa Proportion of Patients by TSS Improvement from ENIGMA Baseline (n=29) 51-52 69-70 aTotal lirentelimab exposure, inclusive of lirentelimab exposure during the Ph

  41. Slide 41: Improvement Across All Symptoms in Patients with ≥70 Weeks of Treatment

    Improvement Across All Symptoms in Patients with ≥70 Weeks of Lirentelimab Treatment EG/EoD-PRO Symptom Score Lirentelimab (n=29) Median Score Baseline Wks 69-70a -87% -88% -100% -99% -96% -90% -65% -94% aTotal lirentelimab exposure, inclusive of lirentelimab exposure during the Phase 2 ENIGMA study

  42. Slide 42: Safety Summary

    Safety Summary Generally well tolerated Most common adverse event (AE) was infusion-related reaction (IRR) Most are mild to moderate (flushing, feeling of warmth, headache, nausea, dizziness) Mostly on first infusion, greatly reduced or does not occur on subsequent infusions No IRRs in 20 patients w

  43. Slide 43: Clinical Development Update

    Clinical Development Update

  44. Slide 44: Clinical Development Update

    Clinical Development Update Phase 3 study in EG/EoD (ENIGMA 2) is well underway On track to have data in 2H21 Phase 2/3 study in EoE (KRYPTOS) is well underway On track to have data in 2H21

  45. Slide 45: Corporate Updates

    Corporate Updates

  46. Slide 46: Strong Balance Sheet and Significant IP Protection

    Strong Balance Sheet and Significant IP Protection Cash, Cash Equivalents and Investments in Marketable Securities as of June 30, 2020 $454.9M H1 2020 Operating Expenses $70.3M Q1 2020 Operating Expenses $29.9M Q2 2020 Operating Expenses $40.4M AK002 US patents first to expire 2035 Lonza currently m

  47. Slide 47: Completed and Near-term Milestones

    Completed and Near-term Milestones H2’20 EGID Prevalence Study Results H2’21 Phase 2/3 EoE Results H2’20 Phase 1 Data For Subcutaneous AK002 Q2’20 Phase 2 Extension Data in EG and/or EoD H2’21 Phase 3 EG and/or EoD Results Completed Completed Completed

  48. Slide 48: Executive Summary

    Executive Summary Registrational study enrollment is well underway Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) Phase 2/3 study in eosinophilic esophagitis (EoE) Phase 1 lirentelimab subcutaneous data 63% bioavailability Well tolerated (no injection site reaction

  49. Slide 49: Q&A

    Q&A

Allakos — Corporate Update (October 2020) on 6ix